Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Akero Therapeutics (AKRO) announced that it has commenced an underwritten public offering of $300M of shares of its common stock. All of the shares in the proposed offering are being offered by Akero.

In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report). The company’s shares closed last Friday at $4.01.

"Tom has an extraordinary talent for transforming groundbreaking science into scalable biotechnology companies focused on developing entirely new ways of treating disease," said Dr. Zaks. "His ...

Meanwhile, Eli Lilly announced plans to acquire Scorpion Therapeutics’ STX-478, a P13K inhibitor which is in phase I trials for breast cancer and other advanced solid tumours. GSK flagged the US$1.15 ...

Lilly also recently announced that it is acquiring a clinical stage drug known as STX-478 from Scorpion Therapeutics for up to $2.5 billion. Lilly's long-term potential doesn't hinge on GLP-1 ...

Lilly also recently announced that it is acquiring a clinical stage drug known as STX-478 from Scorpion Therapeutics for up to $2.5 billion.

Sting from a scorpion Onset of local pain and tingling after a scorpion is seen in the area The main symptoms are pain, tingling and numbness at the sting site About 85% cause only local symptoms at ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Unlock to see our ratings and compare products side by side ...